These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35689497)

  • 21. Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy.
    Zhu H; Song P; Du D; Tian H
    Pediatr Dermatol; 2021 Sep; 38(5):1366-1367. PubMed ID: 34515373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: Extension of the 2PRECISE study.
    Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Jagiello P
    J Am Acad Dermatol; 2021 Feb; 84(2):552-554. PubMed ID: 32565211
    [No Abstract]   [Full Text] [Related]  

  • 23. Impetigo herpetiformis responsive to secukinumab.
    Chhabra G; Chanana C; Verma P; Saxena A
    Dermatol Ther; 2019 Sep; 32(5):e13040. PubMed ID: 31361940
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful secukinumab treatment of recalcitrant juvenile generalized pustular psoriasis.
    Nishida M; Takeichi T; Kono M; Imanishi A; Maekawa N; Akiyama M; Fukai K
    J Dermatol; 2020 Mar; 47(3):e77-e78. PubMed ID: 31907962
    [No Abstract]   [Full Text] [Related]  

  • 25. Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy.
    Yang Y; Xu Q; Zhang Z; Yao Z
    Dermatol Ther; 2022 Apr; 35(4):e15305. PubMed ID: 34994040
    [No Abstract]   [Full Text] [Related]  

  • 26. Infantile generalized pustular psoriasis with excellent response to secukinumab: A case report.
    Guevara BEK; Aquino JMRM; Diaz RBS; Contreras AIT; Jeng YC; Huang HY; Hsu CK; Pandita-Reyes BSB
    Exp Dermatol; 2023 Aug; 32(8):1296-1298. PubMed ID: 36847294
    [No Abstract]   [Full Text] [Related]  

  • 27. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
    Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
    J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secukinumab-induced paradoxical pustular psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Clin Exp Dermatol; 2019 Jan; 44(1):72-73. PubMed ID: 30129214
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report.
    Zheng YX; Zheng M; Cai SQ
    Dermatol Ther; 2022 Nov; 35(11):e15781. PubMed ID: 35986706
    [No Abstract]   [Full Text] [Related]  

  • 31. Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: A case series of high efficacy and safety profile.
    Polat Ekinci A; Bölük KN; Babuna Kobaner G
    Dermatol Ther; 2021 Jan; 34(1):e14704. PubMed ID: 33368934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis.
    Phung M; Ighani A; Georgakopoulos JR; Vender R; Giroux L; Lansang P; Yeung J
    J Cutan Med Surg; 2019; 23(4):391-393. PubMed ID: 30991818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab.
    Honma M; Nozaki H; Hayashi K; Iinuma S; Ishida-Yamamoto A
    J Dermatol; 2019 Dec; 46(12):e468-e469. PubMed ID: 31502309
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
    Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
    Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
    [No Abstract]   [Full Text] [Related]  

  • 36. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
    Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
    J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of secukinumab in psoriasis treatment.
    Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
    Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
    Morita A; Tani Y; Matsumoto K; Yamaguchi M; Teshima R; Ohtsuki M
    J Dermatol; 2020 May; 47(5):452-457. PubMed ID: 32173900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of IL-17 and IL-17 receptor inhibitors in the management of generalized pustular psoriasis.
    Plachouri KM; Chourdakis V; Georgiou S
    Drugs Today (Barc); 2019 Sep; 55(9):587-593. PubMed ID: 31584575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.